Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value
#1213
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Aim(s): To evaluate the clinical relevance and predictive value of EVE-induced HG among pts with advanced NETs.
Materials and methods: Retrospective study of pts with advanced G1-G2 gastroenteropancreatic and lung NETs treated with EVE at 7 Spanish University hospitals. The highest blood sugar level during EVE therapy was considered. A multivariate Cox model controlling for previous diabetes (DM), primary tumour site, grade and prior treatments was used to compare progression-free survival (PFS) across HG CTC grades (gr).
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Custodio A
Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,
Keywords: NET, everolimus, hyperglycemia ,
To read the full abstract, please log into your ENETS Member account.